JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120853

Lithium chloride, GSK3beta inhibitor

Be the first to review this product! Submit a review

|

(5 Publications)

MW 42.39 g/mol, Purity >99%. Direct, non-competitive GSK3β inhibitor in vitro (Ki = 2 mM). Elicits various neuropharmacological effects.
1 Images
Chemical Structure - Lithium chloride, GSK3beta inhibitor (AB120853)
  • Chemical Structure

Lab

Chemical Structure - Lithium chloride, GSK3beta inhibitor (AB120853)

2D chemical structure image of ab120853, Lithium chloride, GSK3beta inhibitor

Key facts

CAS number

7447-41-8

Purity

>99%

Form

Solid

form

Molecular weight

42.39 g/mol

Molecular formula

LiCl

Nature

Synthetic

Solubility

Soluble in water to 100 mM

Biological description

Direct, non-competitive GSK3β inhibitor in vitro (Ki = 2 mM). Elicits various neuropharmacological effects.

IUPAC Name

Lithium chloride

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Need more advice on solubility, usage and handling? Please visit our our product support page for more details.

|

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

|

Refer to SDS for further information.

Product protocols

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 15:7712 PubMed39231947

2024

10-hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl β hydroxylase and inhibiting chondrocyte senescence in male mice preclinically.

Applications

Unspecified application

Species

Unspecified reactive species

Nana Geng,Mengtian Fan,Biao Kuang,Fengmei Zhang,Menglin Xian,Lin Deng,Cheng Chen,Yiming Pan,Jianqiang Chen,Naibo Feng,Li Liang,Yuanlan Ye,Kaiwen Liu,Xiaoli Li,Yu Du,Fengjin Guo

Cell death & disease 14:292 PubMed37185889

2023

Butyrate dictates ferroptosis sensitivity through FFAR2-mTOR signaling.

Applications

Unspecified application

Species

Unspecified reactive species

GuoYan Wang,SenLin Qin,Lei Chen,HuiJun Geng,YiNing Zheng,Chao Xia,JunHu Yao,Lu Deng

Drug design, development and therapy 15:245-257 PubMed33519190

2021

Paeoniflorin Sensitizes Breast Cancer Cells to Tamoxifen by Downregulating microRNA-15b via the FOXO1/CCND1/β-Catenin Axis.

Applications

Unspecified application

Species

Unspecified reactive species

Yanhong Wang,Qian Wang,Xibei Li,Gongwen Luo,Mou Shen,Jia Shi,Xueliang Wang,Lu Tang

Journal of the American Heart Association 9:e015686 PubMed32500803

2020

Enhanced Generation of Induced Cardiomyocytes Using a Small-Molecule Cocktail to Overcome Barriers to Cardiac Cellular Reprogramming.

Applications

Unspecified application

Species

Unspecified reactive species

Vivek P Singh,Jaya Pratap Pinnamaneni,Aarthi Pugazenthi,Deepthi Sanagasetti,Megumi Mathison,Kai Wang,Jianchang Yang,Todd K Rosengart

Frontiers in cellular neuroscience 12:16 PubMed29449801

2018

Lithium Inhibits GSK3β and Augments GluN2A Receptor Expression in the Prefrontal Cortex.

Applications

Unspecified application

Species

Unspecified reactive species

Sarah A Monaco,Brielle R Ferguson,Wen-Jun Gao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com